Get the Stockscreener App
1.75
12.50%
-0.25
After Hours:
1.85
0.10
+5.71%
Femasys Inc stock is traded at $1.75, with a volume of 66,384.
It is down -12.50% in the last 24 hours and down -37.05% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$2.00
Open:
$2
24h Volume:
66,384
Relative Volume:
0.51
Market Cap:
$14.66M
Revenue:
$2.38M
Net Income/Loss:
$-12.40M
P/E Ratio:
-0.2708
EPS:
-6.4626
Net Cash Flow:
$-18.68M
1W Performance:
-13.37%
1M Performance:
-37.05%
6M Performance:
-77.96%
1Y Performance:
-85.71%
1-Day Range:
$1.71
$2.02
1-Week Range:
$1.71
$2.15
52-Week Range:
$1.71
$22.20
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, RMD, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.75 | 14.66M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
427.64 | 151.08B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.89 | 51.45B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
234.60 | 32.99B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.76 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.35 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com Nigeria
Femasys Inc (NASDAQ: FEMY) Share Price, FEMY Stock News, FEMY Share Price & Updates - Kalkine
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance
Femasys Company Profile & Introduction - Moomoo
Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus
FemasysFiles For Resale Of Up To 28,124,997 Shares Of Common StockSEC Filing - TradingView
Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan
Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan
Femasys (FEMY) Stock News & Analysis - TechStock²
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com Canada
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com UK
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayValue Stock Ideas - vinanet.vn
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayComposite Profile - dars.gov.et
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingVolume Dry Up - vinanet.vn
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingHagopian Line - siam.in
Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm
Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com
Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance
Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com
FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com India
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record
Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - marketscreener.com
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Yahoo Finance
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionAnalyst Coverage Count - dars.gov.et
Femasys secures $30 million to advance fertility portfolio - The Pharma Letter
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan
FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan
Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Femasys Inc Stock (FEMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sipos Jeremy Alexander | Chief Technology Officer |
Aug 07 '26 |
Buy |
3.20 |
3,125 |
10,000 |
3,125 |
| Canning John Charles | Chief Operating Officer |
Aug 07 '26 |
Buy |
3.20 |
4,375 |
14,000 |
4,375 |
| Elefant Dov | Chief Financial Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
| Lee-Sepsick Kathy | Chief Executive Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
21.89%
6.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):